

New Products - Signifor

Signifor (**pasireotide diaspertate**) is a cyclohexapeptide, injectable somatostatin analogue. Like natural peptide hormones somatostatin-14 and somatostatin-28 and other somatostatin analogues, pasireotide exerts its pharmacological activity via binding to somatostatin receptors. Five human somatostatin receptor subtypes are known: hsst 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Due to its broad binding profile to somatostatin receptors (high affinity binding to receptor subtypes 1, 2, 3 and 5), pasireotide has the potential to treat diseases characterized by expression of those receptors in the target tissues. Signifor is indicated in adults with Cushing's disease where surgery is unsuitable or has failed. It is contraindicated in severe hepatic impairment (Child-Pugh C). Signifor is available as a solution for injection containing 300 mcg/mL, 600 mcg/mL and 900 mcg/mL in 1 mL glass ampoules in packs of 60's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.